Press release
Diabetes Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight
Diabetes Pipeline
(Albany, USA) "Diabetes Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetes Market.
The Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
To know more in detail about the Diabetes Report and analysis, click here: https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Diabetes Pipeline
• Diabetes Companies across the globe are diligently working toward developing novel Diabetes treatment therapies with a considerable amount of success over the years.
• Diabetes companies working in the market are Nano Precision Medical, Enthera, Pfizer, Scohia Pharma, Carmot Therapeutics, ImCyse, REMD Biotherapeutics, Genexine, Eli Lilly and Company, Dompe Farmaceutici, Oramed, and others, are developing therapies for the Diabetes treatment
• Emerging Diabetes therapies are NPM-119, Ent001, PF 07081532, SCO-094, CT-388, IMCY 0098, Volagidemab, GX G6, LY3209590, Ladarixin, ORMD-0801, and others are expected to have a significant impact on the Diabetes market in the coming years.
• In March 2021, Oramed initiated a trial titled, "A Double-Blind, Placebo-controlled, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in T2DM Subjects With Inadequate Glycemic Control on Diet Control Only or on Diet Control and Metformin Monotherapy"
• In December 2020, Dompé Farmaceutici S.p.A initiated a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy - Safety of 400 mg Twice a Day Oral Ladarixin in Pts With New-onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY)
Diabetes Overview:
Diabetes is a disease that occurs when the blood glucose, also called blood sugar, is too high.
There are a few different types of diabetes:
Type 1 diabetes is an autoimmune disease: The immune system attacks and destroys cells in the pancreas, where insulin is made. It's unclear what causes this attack. About 10 percent of people with diabetes have this type.
Type 2 diabetes occurs when your body becomes resistant to insulin, and sugar builds up in your blood. Prediabetes occurs when your blood sugar is higher than normal, but it's not high enough for a diagnosis of type 2 diabetes. Gestational diabetes is high blood sugar during pregnancy. Insulin-blocking hormones produced by the placenta cause this type of diabetes.
Diabetes Pipeline Therapeutics Assessment
• Diabetes Assessment by Product Type
• Diabetes By Stage and Product Type
• Diabetes Assessment by Route of Administration
• Diabetes By Stage and Route of Administration
• Diabetes Assessment by Molecule Type
• Diabetes by Stage and Molecule Type
Get a Free Sample PDF Report to know more about Diabetes Pipeline Assessment- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's Diabetes Report covers around 200+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Diabetes Drugs Under Different Phases of Clinical Development Include:
• NPM-119: Nano Precision Medical
• Ent001: Enthera
• PF 07081532: Pfizer
• SCO-094: Scohia Pharma
• CT-388: Carmot Therapeutics
• IMCY 0098: ImCyse
• Volagidemab: REMD Biotherapeutics
• GX G6: Genexine
• LY3209590: Eli Lilly and Company
• Ladarixin: Dompe Farmaceutici
• ORMD-0801: Oramed
Diabetes Pipeline Analysis:
The Diabetes pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Diabetes treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
• Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Diabetes product details are provided in the report. Download the Diabetes pipeline report to learn more about the emerging Diabetes therapies - https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Diabetes Pipeline Market Drivers
• Increasing prevalence of diabetes worldwide
• Need for effective treatment with low side effects
• Growing investment in drug development to manage diabetes
Scope of Diabetes Pipeline Drug Insight
• Coverage: Global
• Key Diabetes Companies: , and others
• Key Diabetes Therapies: NPM-119, Ent001, PF 07081532, SCO-094, CT-388, IMCY 0098, Volagidemab, GX G6, LY3209590, Ladarixin, ORMD-0801, and others
• Diabetes Therapeutic Assessment: Diabetes current marketed and Diabetes emerging therapies
• Diabetes Market Dynamics: Diabetes market drivers and Diabetes market barriers
Request for Sample PDF Report for Diabetes Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
Introduction
Executive Summary
Diabetes: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Diabetes - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Diabetes companies' collaborations, Licensing, Acquisition -Deal Value Trends
Diabetes Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Enavogliflozin: Daewoong
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
Golimumab: Janssen Biotech
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase II/I)
• Comparative Analysis
IMCY-0098: ImCyse
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
ENT-001: Enthera
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Diabetes Key Companies
Diabetes Key Products
Diabetes- Unmet Needs
Diabetes- Market Drivers and Barriers
Diabetes- Future Perspectives and Conclusion
Diabetes Analyst Views
Diabetes Key Companies
Appendix
Download Sample PDF Report to know more about Diabetes drugs and therapies by clicking here: - https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Report:
• Adrenal Cortex Neoplasms Market: https://www.delveinsight.com/report-store/adrenal-cortex-neoplasms-market
• Hypothalamic Obesity Market: https://www.delveinsight.com/report-store/hypothalamic-obesity-market
• Pediatric Growth Hormone Deficiency Pghd Market: https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
• Chronic Rhinosinusitis Phenotype With Nasal Polyps Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-phenotype-with-nasal-polyps-market-insight
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Bronchial Spasm Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-intraepithelial-neoplasia-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetes Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight here
News-ID: 3023063 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Emerging trends for Diabetes Care Devices Market 2020 astonishing growth by Worl …
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2020-2027.
Premium market insights recently published a report titled "Diabetes Care Devices Market Size and Forecast to 2026". The report includes an authentic and accurate research study into the global Diabetes Care Devices market based on a qualitative…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
